Tuesday June 27th 2017

Innate Mucosal‐Associated Invariant T (MAIT) cells are activated in Inflammatory Bowel Diseases

Abstract Inflammatory Bowel Diseases are characterized by a deregulated immune response targeting the gut bacterial flora. Mucosal‐Associated Invariant T (MAIT) cells are MHC class Ib‐restricted innate‐like lymphocytes with anti‐bacterial functions. They display an effector/memory phenotype and are found in large numbers in the blood, mucosae and liver. They also have been implicated in inflammatory diseases such as multiple sclerosis. Therefore, we aimed at analyzing the possible involvement of MAIT cells in Crohn’s Disease (CD) and Ulcerative Colitis (UC). To this end, a phenotypic and functional analysis of MAIT cells isolated from the blood of healthy subjects, CD and UC patients was undertaken. MAIT cells were also quantified in ileal biopsies of CD patients. The frequency of …

View this article: 

Innate Mucosal‐Associated Invariant T (MAIT) cells are activated in Inflammatory Bowel Diseases

Leave a Comment

More from category

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…
Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

BACKGROUND: In people with Multiple Sclerosis (pwMS), balance assessment is essential in estimating the risk of falls, [Read More]

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis
CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

The European Medicines Agency ’ s Committee for Medicinal Products for Human Use recommends approval of cladribine to [Read More]

Germany’s Merck gets EU backing for oral MS drug
Germany’s Merck gets EU backing for oral MS drug

FRANKFURT (Reuters) - Germany's Merck KGaA has won a key recommendation to become a late entrant to the market for oral [Read More]

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…
New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

Roche announced today that new post-hoc analyses from the OCREVUS ™ (ocrelizumab) Phase III clinical trial programme [Read More]

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation
MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

/About-the-Society/News/Society-Hosts-Joint-Congressional-Briefing-on-the [Read More]